// // //
Regeneron Pharmaceuticals and Sanofi’s dupilumab has received breakthrough therapy designation from US Food and Drug Administration (FDA) to treat adults with moderate-to-severe atopic dermatitis (AD).
Filed under: Breakthrough Therapy Designation Tagged: Atopic dermatitis, breakthrough therapy status, Dupilumab, fda, regeneron, Regeneron Pharmaceuticals, SANOFI, US Food and Drug Administration
